Rep. Jared Moskowitz Sells West Pharmaceutical Services, Inc. (NYSE:WST) Shares

Representative Jared Moskowitz (D-Florida) recently sold shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on March 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in West Pharmaceutical Services stock on February 13th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (6)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Canadian National Railway (NYSE:CNI) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/15/2025.

West Pharmaceutical Services Trading Down 0.5 %

Shares of NYSE:WST opened at $231.55 on Friday. West Pharmaceutical Services, Inc. has a 52-week low of $197.01 and a 52-week high of $400.88. The stock has a market cap of $16.74 billion, a price-to-earnings ratio of 34.61, a PEG ratio of 6.74 and a beta of 1.09. The company has a quick ratio of 2.23, a current ratio of 2.79 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average price of $297.42 and a 200-day moving average price of $306.29.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.07. The company had revenue of $748.80 million during the quarter, compared to analysts’ expectations of $739.59 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. Equities analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Stockholders of record on Wednesday, April 30th will be paid a $0.21 dividend. This represents a $0.84 annualized dividend and a dividend yield of 0.36%. The ex-dividend date is Wednesday, April 30th. West Pharmaceutical Services’s payout ratio is 12.56%.

Wall Street Analysts Forecast Growth

WST has been the subject of several recent research reports. Wolfe Research initiated coverage on West Pharmaceutical Services in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Deutsche Bank Aktiengesellschaft upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a research report on Friday, February 14th. StockNews.com cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research report on Thursday, February 27th. Citigroup started coverage on West Pharmaceutical Services in a research report on Wednesday, January 8th. They set a “buy” rating and a $400.00 price target for the company. Finally, KeyCorp dropped their price objective on West Pharmaceutical Services from $470.00 to $325.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and an average price target of $344.00.

Institutional Trading of West Pharmaceutical Services

Several institutional investors have recently bought and sold shares of WST. Asset Management One Co. Ltd. grew its holdings in West Pharmaceutical Services by 43.5% in the third quarter. Asset Management One Co. Ltd. now owns 42,048 shares of the medical instruments supplier’s stock valued at $12,621,000 after purchasing an additional 12,745 shares during the period. Impax Asset Management Group plc boosted its stake in shares of West Pharmaceutical Services by 56.1% in the third quarter. Impax Asset Management Group plc now owns 3,067 shares of the medical instruments supplier’s stock worth $921,000 after acquiring an additional 1,102 shares during the last quarter. RTD Financial Advisors Inc. boosted its stake in shares of West Pharmaceutical Services by 120.2% in the third quarter. RTD Financial Advisors Inc. now owns 1,524 shares of the medical instruments supplier’s stock worth $457,000 after acquiring an additional 832 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of West Pharmaceutical Services by 2.3% in the third quarter. Principal Financial Group Inc. now owns 91,756 shares of the medical instruments supplier’s stock worth $27,541,000 after acquiring an additional 2,037 shares during the last quarter. Finally, Kornitzer Capital Management Inc. KS boosted its stake in shares of West Pharmaceutical Services by 1.6% in the third quarter. Kornitzer Capital Management Inc. KS now owns 21,334 shares of the medical instruments supplier’s stock worth $6,404,000 after acquiring an additional 334 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.